MICRO CRISPR (Class 99)

The trademark application number 5373935 is currently marked as "Registered" in the official trademark registry.

The trademark application number 5373935 is owned by MICROCRISPR PRIVATE LIMITED.

Trademark application number 5373935 is filed under Class 99, which relates to the specified goods and services.

Yes, trademark application number 5373935 was published in Journal No. 2053.

Trademark application number 5373935 relates to "[CLASS : 5] Pharmaceutical and biopharmaceutical preparations, agents and substances; diagnostic reagents and assay components for clinical, medical and medical laboratory use; Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections, and inflammatory disease; pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections, and inflammatory disease; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of genetic diseases and disorders. [CLASS : 42] Science and technology services; medical and scientific research; pharmacological research services; laboratory services; gene editing; research and development of therapeutics using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting therapies to individuals; information, advisory and consultancy relating to the aforesaid services.".